Pharmaceutical Market Europe • April 2026 • 36
APPOINTMENTS
BioDuro
Hetal Patel
Biologos, has appointed Hetal Patel as CEO. The appointment follows recent investments in facilities and capabilities, and the acquisition of Biologos by Ampersand in 2024.
Patel brings over 25 years of experience to the role and has been at Biologos since 2024, when she joined as COO. During this time, she helped to ensure operational readiness to support customers and to position the company for long-term growth.
Patel said: “Biologos has an exceptional legacy built on integrity, agility and an unwavering commitment to customers. With Ampersand’s support and the investments we’ve made in our people, facilities and capabilities, we are uniquely positioned to help customers accelerate development timelines, ensure supply continuity and confidently scale from early research through GMP manufacturing.”
IsomAb
Philip Brainin
IsomAb has appointed Philip Brainin as CEO and member of the Board of Directors. In his new role, Brainin will be responsible for advancing the clinical development of ISM-001, a treatment for chronic stable angina (CSA).
With a combination of clinical, medical and venture investing experience, Brainin has invested in multiple early-stage therapeutics companies, supported corporate and business development strategies and advised Boards of Directors, including for AnaCardio and Nephro DI. He previously held roles at Bioinnovation Institute and Sound Bioventures.
Qlaris Bio
Fred Guerard
Qlaris Bio has appointed Fred Guerard as president and CEO. Guerard will also join the Board of Directors. Qlaris develops first-in-class therapies for unmet needs in ophthalmology, including its lead candidate QLS-111 which is designed to treat glaucoma, and Guerard has more than two decades of global leadership experience in ophthalmology.
Previously, Guerard has served as CEO of Othea, president and CEO of Graybug Vision, and worldwide franchise head of ophthalmology at Novartis. He is also non-executive director at CalciMedica and Spiral Therapeutics.
Sandoz
Armin Metzger
Sandoz has appointed Armin Metzger as President, Biosimilar Development, Manufacturing & Supply and a member of the Sandoz Executive Committee. Most recently, Metzger was Executive VP, Chief Technical Operations Officer at Ferring Pharmaceuticals, holding multiple senior technological leadership roles since 2016. Prior to that, he spent nearly 20 years in technological and scientific leadership roles at Merck and Merck Serono.
BOOST Pharma
Elaine Jones
BOOST Pharma has appointed Elaine Jones as Chair of its Board of Directors. Having served on over 35 company boards during her career, Jones brings more than 20 years of experience to the role. Her previous roles include Vice President of Venture Capital at Pfizer Ventures and multiple leadership roles at GSK’s corporate venture fund, SR One. Jones is currently Chair of Mironid and a member of the Board of the Novartis Venture Fund.
ReproNovo
Mark Altmeyer
Biologos has appointed Hetal Patel as CEO. Patel brings over 25 years of experience to the role and has been at Biologos since 2024, when she joined as Chief Operating Officer. During this time, she helped to ensure operational readiness to support customers and to position the company for long-term growth.
Pharmaceutical Market Europe (PME)
Pharmaceutical industry news, articles, jobs, reports, advice and services